Radioimmunoconjugates (RICs) are radionuclides conjugated to monoclonal antibodies. The goal of radioimmunotherapy is to target radiation to tumor tissue while limiting the toxicity to normal cells. Our goal is to make a significant contribution in making alpha-particle radioimmunotherapy a new standard cancer treatment. The low dose rate of the treatment suggests that the bystander effect may be an important contributor to the therapeutic outcome.


KEY ACHIEVEMENTS
²²⁷Thorium-rituximab targets and inhibits growth of CD20 positive tumors, (Blood, 2007).


GROUP MEMBERS
Principal investigator: Jostein Dahle
PhD-students: Nasir Abbas, Erta Kalanxhi and Helen Heyerdahl
Technicians: Cecilie Krogh, Anne Kristine Hjelmerud and Katrine Melhus
MSc-student: Hans Magnus Hopen